Followers | 2775 |
Posts | 77901 |
Boards Moderated | 1 |
Alias Born | 05/10/2007 |
Monday, March 02, 2020 11:29:18 PM
OpGen filed and furnished to its stockholders a proxy statement/prospectus and a notice of special meeting of OpGen stockholders to be held on March 10, 2020 to approve the business combination with Curetis. On the same day at 1:00pm CET, Curetis will host its extraordinary shareholder
meeting with the objective of seeking approval from its shareholders for the planned business combination with OpGen.
Curetis GmbH’s subsidiary Ares Genetics’ collaboration with BGI Group to offer Next-Generation Sequencing (NGS) and PCR-based Coronavirus (2019-nCoV) testing in Europe.•Curetis GmbH and Quaphaco entered into an exclusive distribution partnership for Vietnam for an initial term of three years with Quaphaco committing to a minimum purchase.
OpGen, Inc. (Nasdaq: OPGN) reported an update on the business of Curetis GmbH (“Curetis”), the other party to the planned business combination with OpGen.
Recent OPGN News
- OpGen Provides Update on Business Operations and Strategic Opportunities • GlobeNewswire Inc. • 04/29/2024 08:05:00 PM
- OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K • GlobeNewswire Inc. • 04/23/2024 08:15:00 PM
- Shares Rip In Reaction To Activist Investor Becoming CEO • AllPennyStocks.com • 03/26/2024 08:20:00 PM
- OpGen Announces Acquisition of Preferred Stock by David Lazar • GlobeNewswire Inc. • 03/25/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 12:30:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 09:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:58:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:37:15 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/24/2023 05:15:18 AM
- OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2023 09:59:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:30:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 08:30:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/13/2023 09:18:03 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/13/2023 09:17:02 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/13/2023 09:15:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/13/2023 09:14:21 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/13/2023 09:13:12 PM
- OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds • GlobeNewswire Inc. • 10/12/2023 04:32:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 08:40:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 08:30:10 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 09/28/2023 08:24:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:30:09 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM